Assessment of the Potential Impact of Mycophenolate Mofetil on Lowering Renal Biomarkers in Patients with Class III Lupus Nephritis: A Pilot Study to Predict Renal Function Progress

Basit Öğe Kaydı
dc.authorscopusidAnmar Al-Taie / 57221579036
dc.authorwosidAnmar Al-Taie / I-8549-2019
dc.contributor.authorMohammed, Nadia H.
dc.contributor.authorAl-Taie, Anmar
dc.contributor.authorAl-Sultany, Fadia H.
dc.date.accessioned2025-06-03T13:14:42Z
dc.date.available2025-06-03T13:14:42Z
dc.date.issued2024
dc.departmentİstinye Üniversitesi, Eczacılık Fakültesi, Eczacılık Temel Bilimleri Bölümü
dc.description.abstractBackground: Lupus nephritis (LN) is a potentially severe complication of systemic lupus erythematosus (SLE). Mycophenolate mofetil (MMF) is an oral immunosuppressive agent used in lupus patients who are intolerant of or refractory to other conventional therapies. The aim of this study was to assess the potential effect of MMF on lowering some biomarkers as a predictive of renal function in patients with Class III LN. Methods: This was a single-center, prospective cohort study that enrolled patients with Class III LN who received 2 g/day of oral MMF. The potential impact of MMF on renal biomarkers was evaluated at baseline and subsequently at 3-month intervals for 6 months according to changes in antinuclear antibodies (ANA), antidouble stranded deoxyribonucleic acid (anti-dsDNA), elastase α-1 proteinase inhibitor (α-1 PI), proteinuria, and the urine protein-to-creatinine ratio (P/C ratio). Results: A significant decrease over the course of MMF treatment compared to the baseline regarding ANA (1.37 ± 0.47 vs. 2.90 ± 1.05, P = 0.03); anti-dsDNA (23.39 ± 3.19 vs. 39.91 ± 8.1 IU/mL, P = 0.02); elastase α-1 PI (512.4 ± 74.12 vs. 696.35 ± 105.35 ng/mL, P = 0.03); proteinuria (0.25 ± 0.44 vs. 1.95 ± 0.76 g/24 h., P = 0.01); and P/C ratio (0.20 ± 0.22 vs. 1.37 ± 0.26, P = 0.04). Conclusion: MMF is effective in lowering renal biomarkers of Class III LN revealed by a significant reduction in ANA, anti-dsDNA, elastase α-1 PI, proteinuria, and P/C ratio over 6 months of MMF treatment. Copyright © 2024 Biomedical and Biotechnology Research Journal (BBRJ).
dc.identifier.citationMohammed, N. H., Al-Taie, A., & Al-Sultany, F. H. (2024). Assessment of the Potential Impact of Mycophenolate Mofetil on Lowering Renal Biomarkers in Patients with Class III Lupus Nephritis: A Pilot Study to Predict Renal Function Progress. Biomedical and Biotechnology Research Journal (BBRJ), 8(3), 369-374.
dc.identifier.doi10.4103/bbrj.bbrj_16_24
dc.identifier.endpage374
dc.identifier.issn25889834
dc.identifier.issue3
dc.identifier.scopusqualityQ2
dc.identifier.startpage369
dc.identifier.urihttp://dx.doi.org/10.4103/bbrj.bbrj_16_24
dc.identifier.urihttps://hdl.handle.net/20.500.12713/7279
dc.identifier.volume8
dc.identifier.wosWOS:001409744200013
dc.identifier.wosqualityQ4
dc.indekslendigikaynakScopus
dc.indekslendigikaynakWeb of Science
dc.institutionauthorAl-Taie, Anmar
dc.institutionauthoridAnmar Al-Taie / 0000-0002-2183-6830
dc.language.isoen
dc.publisherWolters Kluwer Medknow Publications
dc.relation.ispartofBiomedical and Biotechnology Research Journal
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectElastase α-1 Proteinase Inhibitor
dc.subjectLupus Nephritis
dc.subjectRenal Biomarkers
dc.titleAssessment of the Potential Impact of Mycophenolate Mofetil on Lowering Renal Biomarkers in Patients with Class III Lupus Nephritis: A Pilot Study to Predict Renal Function Progress
dc.typeArticle

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Eczacılık Meslek Bilimleri Bölümü Makale Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu